Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InflaRx N.V.
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 24, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 24, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 24, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
May 21, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
May 19, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
May 19, 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
May 17, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
May 17, 2026
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
May 16, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
May 16, 2026
1
2
Next Page
→